Navicixizumab

Tax included
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.
MedChemExpress 
HY-P99377

Data sheet

Size
Multiple sizes
Reactivity
Notch
Application
Cancer-programmed cell death
CAS
1638338-43-8